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Background. The epidemiology of congenital malaria was investigated in a hospital-based malaria surveillance
study in Papua, Indonesia.
Methods. From April 2005 to January 2010, 4878 delivering women and their newborns underwent prospective
clinical review and malaria screening by peripheral blood microscopy.
Findings. Congenital malaria occurred in 8 per 1000 (38/4884) live births, with Plasmodium falciparum
accounting for 76.3% (29) and P. vivax for 15.8% (6) of infections. Maternal malaria at delivery (adjusted odds ratio
[AOR], 9.5; 95% conﬁdence interval [CI], 4.2–21.5; P , .001), age # 16 years (AOR, 4; 95% CI, 1.4–12.1; P 5 .011),
and prior malaria during pregnancy (AOR, 2.2; 95% CI, 1.1–4.4, P 5 .022) were independent risk factors for vertical
transmission. Of 29 mothers and neonates with contemporaneous peripheral parasitemia, 17% (5) had discordant
parasite species, suggesting possible antenatal malaria transmission. Newborns with malaria were at signiﬁcantly
greater risk of low birth weight (AOR, 2.8; 95% CI, 1.2–6.6; P 5 .002). Following introduction of dihydroartemisinin-
piperaquine for uncomplicated malaria in the second and third trimesters of pregnancy, congenital malaria incidence
fell from 3.2% to 0.2% (odds ratio, 0.07; 95% CI, .03–.15; P , .001).
Conclusions. Congenital malaria is an important cause of neonatal morbidity in this region co-endemic for
P. falciparum and P. vivax malaria. The introduction of artemisinin-combination therapy was associated with
a signiﬁcant risk reduction in the vertical transmission of malaria.
In areas where malaria is endemic, the risk of malaria
starts in the early neonatal period, with congenital in-
fections recognized as an important cause of morbidity
[1–4]. The asymptomatic nature of infection in the early
stages is likely to result in its true incidence being un-
derestimated [5, 6].
In highly endemic areas of Africa, up to a third of
infants acquire malaria in utero [7–10]. Vertical trans-
mission is less well described in the Asia Paciﬁc region,
descriptions of its epidemiology often relying on case
series/reports or maternal or placental malaria studies
that are generally of small sample size [11–15]. In the
present study we sought to deﬁne the risks of vertical
malaria transmission along with its treatment and pre-
vention in . 4000 neonates born in the local hospital in
Timika, Papua-Indonesia, an area with highly prevalent
drug-resistant Plasmodium falciparum and P. vivax [16].
METHODS
Study Site
The study was conducted in southern Papua, Indonesia.
This area is largely forested, with both coastal and
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lowland area, where it is associated with 3 mosquito vectors:
Anopheles koliensis, A. farauti,a n dA. punctulatus. Until No-
vember 2008, Rumah Sakit Mitra Masyarakat (RSMM) hospital,
Timika, was the only hospital in this district servicing an area of
21522 km
2, with a population of 200000 people. The annual
incidence of malaria in the region is 876 per 1000 person-years,
divided 60:40 between P. falciparum and P. vivax infections
[17]. In this region, high levels of antimalarial drug resistance
are present in both species, the risk of failure within 28 days
reaching 65% after chloroquine monotherapy for P. vivax and
48% after chloroquine plus sulfadoxine-pyrimethamine for
P. falciparum [16].
Study Population
The infant mortality rate in southern Papua is estimated as
68 per 1000 live births [18], with malaria being the most com-
mon cause of morbidity in the ﬁrst year of life, followed by
diarrhea and lower respiratory tract infections [19]. Malaria
accounts for 30% and 14% of infant hospital admissions and
outpatient visits, respectively [4]. Due to economic migration,
the ethnicorigin ofthe local populationisdiverse, with highland
Papuans, lowland Papuans, and non-Papuans all resident in the
region. Hospital policy dictates that all patients presenting with
a febrile illness, irrespective of other symptoms, should have
blood ﬁlm examination for malaria.
Data Collection
From April 2004 hospital protocol dictated that all infants born
at RSMM were to be screened for malaria within 3 days of birth.
After obtaining parental/legal guardian consent, the malaria
smear results were documented, and a trained research nurse or
research physician performed systematic physical examination
of the baby to assess clinical signs, gestational age (using New
Ballard Score) [20], and the presence of external congenital
malformations.Babieswithabirthweight, 2500gweredeﬁned
as having a low birth weight (LBW), and those with gestational
age of , 37 weeks, as being premature. External congenital
malformation was diagnosed based on the International Classi-
ﬁcation of Diseases 10 [21]. Maternal clinical and laboratory data
at delivery were also collected as described elsewhere [22].
If the newborn had malaria, a more detailed questionnaire on
clinical and laboratory data was completed. In order to de-
termine late congenital manifestations, all infants younger than
3 months old admitted with malaria to the pediatric wards were
identiﬁed and invited to be part of the study. In the latter case
maternal data at delivery were retrieved from hospital records if
the infant was born at RSMM. A research nurse documented
history of illness (including fever, restlessness, poor feeding,
cough, and breathlessness) and weight of the infants. The infant
was examined, and pulse, respiratory rate, and the presence of
splenomegaly and hepatomegaly were recorded. Temperature
was recorded per axilla, with fever deﬁned as a temperature
.37.5C. Severe anemia was deﬁned as having hemoglobin
concentration ,5g / d L[ 23].
Malaria was diagnosed by microscopy of Giemsa-stained
blood ﬁlms. Slides were read by an expert microscopist and
considered negative after review of 200 high-power ﬁelds. Par-
asite counts were determined from the number of parasites per
200 white blood cells (WBC) on Giemsa-stained thick ﬁlms.
Peripheral parasitemia was calculated from the recorded white
cell count. A thin smear was also examined to conﬁrm parasite
species and used for quantiﬁcation if parasitemia was . 200 per
200 WBC.
As clinically indicated, venous blood samples (1–5 mL) were
drawn from infants admitted with malaria to the pediatric
wards for complete blood counts and hemoglobin concen-
tration (using electronic counterdCoulter JT). Venous sam-
pling was not routinely conducted in neonates (age , 28 days)
with peripheral malaria parasitemia unless requested by the
attending clinician.
All infants with peripheral parasitemia received standard
antimalarial therapy and supportive care as per hospital pro-
tocol. Before March 2006, young infants and pregnant women
with uncomplicated malaria of any species were treated with
quinine for 7 days (intravenous quinine was used for severe
malaria). After March 2006, local protocols were changed to
recommend dihydroartemisinin-piperaquine (DHP) for un-
complicated malaria in infants weighing . 5 kg and in pregnant
women in the second and third trimesters of pregnancy. Neo-
nates weighing , 5 kg were treated with oral quinine, and
women in the ﬁrst trimester, with quinine and clindamycin.
Neonates and pregnant women with severe malaria were treated
with intravenous artesunate [24].
Statistical Analysis
Data from the questionnaire and the laboratory were entered
into EpiData 3.02 software (EpiData Association). Data were
analyzed using SPSS vs 17.0 for Windows software (SPSS Inc).
NormallydistributeddatawerecomparedbyStudentt test.Data
not conforming to a normal distribution were compared by the
Mann–Whitney U test. Categorical data were compared by
calculating the v
2 with Yates’s correction or by Fisher’s exact test
and the odds ratio (OR) with 95% conﬁdence intervals (CIs).
Multiple logistic regression wasusedtoanalyze independent risk
factors for congenital malaria by entering all signiﬁcant risk
factors in univariate analysis.
Ethical Approval
Ethical approval for this study was obtained from the ethics
committees of the National Institute of Health Research and
Development, Ministry of Health, Indonesia; and the Human
Research Ethics Committee of the Menzies School of Health
Research and Department of Health, Darwin, Australia.
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Congenital Malaria
Between April 2004 and January 2010, 4884 (85%) of 5728 ba-
bies born at RSMM were screened for malaria (Figure 1). In
total, 38 (0.8%) neonates were diagnosed with congenital in-
fection within the ﬁrst 3 days of life. P. falciparum accounted for
76.3% (29) of infections; P. vivax, for 15.8% (6); P. ovale,f o r
2.6% (1); and mixed species, for 5.3% (2). There was 1 pair of
twins with congenital malaria, both of whom had P. falciparum.
The median parasite density of the newborns was 100 lL
21
(range, 50–26 700 lL
21). All newborns were asymptomatic,
with the exception of 1 baby with high parasitemia and severe
malaria manifest as neonatal sepsis syndrome, as reported pre-
viously[25].Themedianparasitemiawassimilarbetweeninfants
infected with P. falciparum (100 lL
21; range, 50–26688 lL
21)
and P. vivax (125 lL
21; range, 50–300 lL
21; P 5 1.0).
Newborns with congenital malaria had a lower birth weight
(mean, 2764; 95% CI, 2553–2975 g; with 32.4% [12/37] having
LBW), compared with newborns without malaria (mean, 3031;
95% CI, 2997–3028 g; 13.3% (642/4838) with LBW; P 5 .02),
the OR for LBW being 3.1 (95% CI, 1.6–6.3; P 5 .002). The
effect of congenital malaria on LBW remained after controlling
for other known risk factors in this population (maternal age,
parity, maternal malaria, and severe anemia; adjusted odds
ratio [AOR], 2.7; 95% CI, 1.1–6.5; P 5 .03).
Antimalarials were given to all parasitemic newborns, with 32
receiving quinine (oral 6 intravenous); 2, intravenous artesu-
nate followed with DHP; and 4, oral DHP alone. All malaria
smears were negative at time of discharge from hospital.
Maternal Parasitemia and Vertical Transmission
Data on the blood ﬁlm examination of the mothers were
available in 4878 women, the prevalence of maternal malaria
being 19% (928; Table 1). Of the 37 recorded cases of early
vertical transmission, 9 (24%) were born from aparasitemic
mothers. In the remaining 28 women with malaria at delivery,
5 had neonates with different parasite species, giving rise to
discordance in 18% of cases (Table 1).
Maternal Risk Factors
Maternal risk factors for vertical transmission are shown in
Table 2. The risk of vertical transmission was 3% in women
with peripheral parasitemia at delivery compared with 0.2%
in those aparasitemic (OR, 13.6; 95% CI, 6.4–28.9; P , .001),
with the population attributable risk of congenital infection
being 70%. The risk of transmission did not vary with mag-
nitude of maternal peripheral parasitemia even after control-
ling for the species of infection (Table 3). Afebrile mothers
with malaria had a risk of transmitting the parasites verti-
cally (2.5%, 16/642) comparable to symptomatic parasitemic
mothers (4.2%, 12/284; P 5 .21). Regardless of parasitemia
status at delivery, women with possible history of malaria in-
fection during pregnancy had a 4.1-fold (95% CI, 2.1–7.9)
greater risk of vertical transmission to the fetus compared with
mothers without any history of malaria infections (P , .001).
In the multivariate models, maternal malaria at delivery, his-
tory of malaria during pregnancy, and maternal age # 16 years
old remained as independent risk factors for vertical trans-
mission (Table 2). Together these factors explained 89% of all
congenital infections.
Figure 1. Study profile.
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In total 905 pregnant women described a prior febrile episode
during their pregnancy and were treated with antimalarial
medication, with vertical transmission of infection observed in
18 (2%) births. DHP was introduced as ﬁrst-line treatment of
uncomplicated malaria in the second and third trimesters of
pregnancy since March 2006. Babies born of mothers with
a history of DHP treatment during pregnancyhada signiﬁcantly
lower risk of malaria (0.2%, 1/471) compared with those with
prior exposure to chloroquine/quinine treatment (4.9%, 17/348;
OR, 0.04; 95% CI, .005–.3; P , .001). The number of congenital
malaria cases declined signiﬁcantly following the change in ma-
laria treatment policy, from 3.2% (29/907) before policy change
to 0.2% (9/3912) after (OR, 0.07; 95% CI, .03–.15; P , .001).
There has been no reported congenital malaria case since
October 2008 (Figure 2). After controlling for other con-
founding factors, malaria treatment policy change remained
as a protective factor for congenital malaria (AOR, 0.18; 95%
CI, .032–.89; P 5 .036).
Possible Late Manifestation of Congenital Infection
Of 4878 hospital deliveries, 74 infants from 72 mothers (66
singletons, 4 half twins, and 2 sets of twin) were readmitted to
the hospital in the ﬁrst 3 months of life with symptomatic ma-
laria. All ofthese infants had been screened at birth with negative
blood ﬁlms. On readmission, P. falciparum accounted for 20%
(15), P. vivax for 76% (56), and mixed species for 4% (3) of the
infections.Oneinfant(92daysold)withmixedP.falciparumand
P. vivax malaria had severe anemia and died within 24 hours of
hospitalization. All other children were discharged from hospital
after a median of 3 days’ (interquartile range, 1–2) inpatient stay.
The major maternal factors associated with admission of an
infant to hospital with malaria in the ﬁrst 3 months of life
were maternal malaria at delivery (OR, 3.3; 95% CI, 2.1–5.3;
P , .001) and a history of malaria during pregnancy (OR, 1.8;
95% CI, 1.1–3; P 5 .024). LBW infants and twins had a 2.3-
fold (95% CI, 1.3–3.8; P 5 .005) and 3.5-fold (95% CI, 1.6–
7.9; P 5 .01) higher risk of malaria in early life compared with
those with normal birth weight and singletons, respectively.
Table 1. Vertical Malaria Transmission Profile
Maternal parasitemia
Parasitemia at birth
a
Negative
Plasmodium
falciparum P. vivax P. ovale
Mixed
infection
Overall vertical
transmission
Negative (n 5 3948) 3939 (99.8) 8 (0.2) 1 (0.02) 0 0 9 (0.2)
P. falciparum (n 5 501) 488 (97.2) 12 (2.4) 1 (0.2) 0 0 13 (2.5)
P. vivax (n 5 321) 314 (97.8) 3 (0.9) 4 (1.2) 0 0 7 (2.2)
P. ovale (n 5 3) 2 (66.7) 0 (0) 0 (0) 1 (33.3) 0 1 (33.3)
P. malariae (n 5 50) 49 (98) 1 (2) 0 (0) 0 0 1 (2)
Mixed infection (n 5 53) 47 (88.7) 4 (7.5)/3 0 (0) 0 2 (3.8)/2 6 (11)
All data are no. of cases (%).
a Where deliveries included multiple births, vertical transmission was reported if at least 1 of the babies was found to be parasitemic.
Table 2. Maternal Risk Factors for Vertical Malaria Transmission
Risk factor
Prevalence n/valid
cases (%)
Prevalence of cases
exposed to factor
n/valid cases (%)
Univariate analysis
PAR
Multivariate analysis
PAR OR (95%CI) P value AOR (95%CI) P value
Maternal peripheral parasitemia
at birth
928/4878 (19) 28/37 (75) 13.6 (6.4–28.9) ,.001 70% 9.5 (4.2–21.5) ,.001 68%
No. 3950/4878 (81) 9/37 (24) .. . 11 .
P. falciparum malaria 501/4878 (10) 13/37 (35) 11.6 (4.9–27.4) ,.001 32% 7.6 (2.9–19.4) ,.001 30%
P. vivax malaria 321/4878 (6.6) 7/37 (18.9) 9.7 (3.6–26.4) ,.001 17% 6.9 (2.4–19.3) ,.001 16%
Maternal fever 365/4877 (7.5) 13/37 (35) 6.9 (3.5–13.7) ,.001 30% 1.6 (.8–3.4) .207 13%
Maternal history of febrile illness 925/4881 (19) 18/37 (48.6) 4 (2.1–7.9) ,.001 36% 2.2 (1.1–4.4) .022 26%
Young mother (, 16 years old) 118/4879 (2.4) 4/37 (10.8) 5 (1.7–14.4) .012 8.6% 4.1 (1.4–12.1) .011 8.2%
Primipara 1527/4878 (31) 12/37 (32.4) 1.05 (.5–2.1) .860 .. . .
Severe anemia 333/4740 (6.8) 3/36 (8.3) 1.2 (.4–3.9) .74 .. . .
Preterm delivery 748/4865 (15.3) 8/37 (21.6) 1.5 (.7–3.3) .260 .. .
Abbreviations: AOR, adjusted odds ratio; CI, conﬁdence interval; OR, odds ratio; PAR, population attributable risk, calculated as [(proportion of cases exposed to
risk factor) 3 (OR – 1)]/OR.
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This large surveillance study deﬁnes the epidemiology of con-
genital malaria and its outcome after treatment in Papua, In-
donesia, an area co-endemic for both vivax and falciparum
malaria. Congenital malaria was observed in 0.8% of live births,
with the risk of vertical transmission rising almost 10-fold in
women with peripheral parasitemia at delivery. This incidence
was signiﬁcantly lower than that reported from areas of high
malaria transmission in Africa, which, with some exceptions
[26], has generally ranged from 5% to 33% [8–10] and even
higher (19%–50%) in women with peripheral parasitemia
[7, 9, 10]. Contrary to previous hypotheses, these ﬁndings
suggest that vertical transmission may be determined by other
factors than just the level of malaria exposure and associated
maternal immunity [27].
In almost 20% of cases the parasite species in the baby was
discordant with the peripheral parasitemia of the mother. Ver-
tical transmission of malaria occurring antenatally is well de-
scribed in both African andSoutheast Asian settings[8, 9, 11, 14,
25, 28, 29], and this may explain some of the materno-neonatal
discordance in parasite species. In addition, the vertical trans-
missionofinfectionmayreﬂectthespeciesofplacentalinfection,
in which case the peripheral parasitemia may be an incidental
ﬁnding. However, because we did not routinely examine pla-
cental tissue, we were unable to investigate this further.
Most reports of congenital malaria originate from sub-
Saharan Africa, where the majority of infections are due to
P. falciparum. The epidemiology of congenital infection in Asia
and South America is less well described. In these regions, where
P. falciparum and P. vivax are co-endemic, vertical transmission
can occur with either species [11, 14]. In the present study we
routinely screened all babies within 3 days of birth and were thus
able to reliably exclude infections acquired early in the postnatal
period. P. vivax congenital infection (alone or mixed) occurred
in 1.6 per 1000 live births and accounted for 22% of all con-
genital infections. Although the median P. falciparum para-
sitemia observed in newborns in Papua was higher (100 lL
21;
range, 50–26 688 lL
21) than that reported in Africa (48 lL
21;
range, 8–200 lL
21)[ 9], infections in Papua were almost all
asymptomatic, compared with a third of infections being
symptomatic in an African study undertaking active screening.
These ﬁndings could not be explained by early detection since in
both studies active screening was conducted at birth.
Fetal exposure to malarial parasites in utero has been pro-
posed to modify the immune response of newborns, increasing
their susceptibility to symptomatic malaria infections at birth
and later in life [30–32]. In Africa, where peripheral parasitemia
and placental malaria are highly prevalent, this increased sus-
ceptibility is associated with a greater risk of neonatal para-
sitemia and clinical malaria [27, 33]. In such settings neonatal
Table 3. Maternal Parasitemia at Delivery and Vertical Malaria
Transmission
Maternal
parasitemia
(geometric mean/lL)
Vertical
malaria
transmission
P value Present Absent
P. falciparum 403 (81–1998) 1480 (1211–1998) .098
P. vivax 2186
a 665 (200–1998) ...
a One case only.
0
1
2
3
4
5
Number of Cases
Figure 2. Number of congenital malaria cases per month. Treatment policy for pregnant women in second and third trimesters changed to
dihydroartemisinin-piperaquine in March 2006.
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lower-transmission areas the consequence of leaving asymp-
tomatic congenital malaria untreated may be signiﬁcantly as-
sociated with greater malaria morbidity in early life [4]. As such,
early detection by active screening of all babies is warranted
where resources permit.
African infants with congenital malaria are at greater risk of
LBWthan aparasitemic infants [7,10],anda similarobservation
was apparent in our Papuan study. Premature delivery associ-
ated with maternal malaria could not explain this increased risk,
suggesting that other factors such as placental infection and
insufﬁciency may play a crucial role in reducing fetal growth
[34].
Our study highlights the importance of ensuring the effective
treatment of maternal malaria. DHP has excellent efﬁcacy
against both multidrug-resistant P. falciparum and P. vivax.
In March 2006 local guidelines for the treatment of maternal
malaria in the second and third trimesters of pregnancy were
changed from chloroquine plus sulfadoxine-pyrimethamine or
quinine to DHP. Over the ensuing 3 years this policy has been
associated with a large reduction in the incidence of congenital
malaria. Indeed we have not witnessed a case of congenital
malaria since October 2008, despite screening almost 1416 ba-
bies for malaria. Chloroquine and sulfadoxine-pyrimethamine
have been the main treatment options for maternal malaria in
most parts of Africa [9, 35, 36], but these policies are threatened
by high rates of aminoquinoline and antifolate drug resistance.
This may in part explain the high rates of congenital malaria
reported from a number of sites in the continent [7, 9, 10]a n d
further emphasizes the need for exploring more effective and
reliable treatment strategies in pregnancy. In Kenya, congenital
malaria has fallen in recent years in parallel with the fall in
general community malaria burden, suggesting that malaria
control interventions targeting the whole community may also
contribute to reductions in congenital malaria [26].
There are a number of limitations to our study. We were
reliant on microscopy of peripheral blood ﬁlm for diagnosing
malaria,and thisislikely tohave underestimated the realburden
of congenital malaria by missing low-parasitemia infections and
misdiagnosis of the species of infection [37]. The use of poly-
merase chain reaction diagnostics in previous reports may have
detected a higher proportion of infections [29]. In addition, the
lack of cord blood parasitemia and placental malaria data in our
study will have also underestimated the true burden of con-
genital malaria [9, 29]. The risks to the baby documented in this
article are therefore conservative estimates.
Currently, there are no consensus international guidelines for
the case management of congenital malaria. In Africa asymp-
tomatic congenital malaria is often left untreated if the parasites
are cleared within 3 days [10]. Chloroquine and sulfadoxine-
pyrimethamine have been used previously for treating congen-
ital falciparum malaria [7, 38], but with increasing antimalarial
drug resistance, these treatments can no longer be advocated
[16, 39].
At our study site all infants with positive blood ﬁlms were
treated with antimalarial drugs irrespective of symptomatology;
however,treatment options inthis regionarelimited[4].Due to
the highprevalence ofmultidrugresistanceinbothP.falciparum
and P.vivax[16],localguidelines recommendthat infants ,5kg
in weight with malaria should be treated with either a 7-day
course of oral quinine or, if unable to tolerate oral medication,
intravenous artesunate followed with DHP. In the current re-
port all infants responded well to treatment, although they were
not systematically followed up after discharge from hospital.
The reality is that compliance with unsupervised 7-day courses
of oral quinine is rare, and as a result, late recurrence rates are
high [16]. Therefore, evidence for the safety and efﬁcacy of
reliable short-course treatment regimens is urgently required
for malaria in neonates and young infants.
In conclusion, our study provides insights into the epidemi-
ology of congenital malaria in endemic areas outside Africa. The
introduction of a highly effective artemisinin combination
therapy for malaria treatment in the second and third trimesters
of pregnancy was associated with a marked decrease in the risk
of congenital malaria. Routine screening of newborns for
asymptomatic parasitemia followed by prompt, effective anti-
malarialtreatmentcouldreducemalariaburdeninearlylifeeven
further.
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